{"hands_on_practices": [{"introduction": "The diagnosis of an insulinoma, a functional pancreatic neuroendocrine tumor, hinges on biochemically proving endogenous hyperinsulinism during hypoglycemia. Before proceeding with surgical exploration, a surgeon must be adept at interpreting the results of a supervised fast, which remains the gold standard for diagnosis. This exercise challenges you to apply the precise quantitative criteria—evaluating plasma glucose, insulin, C-peptide, and proinsulin levels simultaneously—to confirm the diagnosis and solidify the indication for surgery. [@problem_id:4652669]", "problem": "A patient with recurrent fasting neuroglycopenic symptoms undergoes a supervised fast. At symptom onset, simultaneous plasma measurements are obtained: $[\\text{glucose}]=45\\,\\text{mg/dL}$, $[\\text{insulin}]=6\\,\\mu\\text{U/mL}$, $[\\text{C-peptide}]=0.3\\,\\text{nmol/L}$, and $[\\text{proinsulin}]=15\\,\\text{pmol/L}$. A comprehensive sulfonylurea and meglitinide screen is negative. Using the standard, widely accepted biochemical criteria for endogenous hyperinsulinemic hypoglycemia in insulinoma during a supervised fast, define the diagnostic indicator $D$ by $D=1$ if the criteria are met and $D=0$ otherwise. Compute $D$. The final answer must be a single real number with no units. No rounding is required.", "solution": "The user wants me to solve a problem.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n\nThe problem provides the following information about a patient with recurrent fasting neuroglycopenic symptoms who underwent a supervised fast:\n-   At symptom onset, simultaneous plasma measurements were:\n    -   $[\\text{glucose}] = 45\\,\\text{mg/dL}$\n    -   $[\\text{insulin}] = 6\\,\\mu\\text{U/mL}$\n    -   $[\\text{C-peptide}] = 0.3\\,\\text{nmol/L}$\n    -   $[\\text{proinsulin}] = 15\\,\\text{pmol/L}$\n-   A comprehensive sulfonylurea and meglitinide screen is negative.\n-   A diagnostic indicator $D$ is defined as $D=1$ if the standard biochemical criteria for endogenous hyperinsulinemic hypoglycemia in insulinoma are met, and $D=0$ otherwise.\n-   The task is to compute the value of $D$.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem is evaluated against the established criteria for validity:\n\n-   **Scientifically Grounded:** The problem is firmly rooted in the established clinical and biochemical principles of endocrinology and general surgery for the diagnosis of insulinoma. The concept of a supervised fast, the measurement of glucose, insulin, C-peptide, and proinsulin, and the use of a drug screen are all standard-of-care diagnostic procedures. The provided values are clinically plausible.\n-   **Well-Posed:** The problem gives a complete set of data and a clear, unambiguous task: to apply a well-defined set of diagnostic criteria. The criteria for diagnosing endogenous hyperinsulinemic hypoglycemia are standardized in medical literature, leading to a unique and meaningful solution.\n-   **Objective:** The problem is based on objective, quantitative laboratory measurements and asks for an evaluation against \"standard, widely accepted biochemical criteria,\" which are objective and not subject to opinion.\n\nThe problem exhibits none of the flaws that would render it invalid. It is scientifically sound, well-posed, objective, complete, and directly relevant to the specified topic.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. Proceeding with the solution.\n\n**Solution**\n\nThe objective is to determine the value of the diagnostic indicator $D$ based on whether the patient's laboratory results meet the standard criteria for endogenous hyperinsulinemic hypoglycemia, which is the hallmark of an insulinoma. The diagnosis requires the presence of hypoglycemia accompanied by inappropriately high levels of insulin and its precursors, with exclusion of exogenous causes. We will evaluate the given data against each criterion.\n\nThe standard diagnostic criteria, often evaluated at the end of a supervised fast when symptoms of neuroglycopenia occur, are as follows:\n\n1.  **Plasma Glucose:** A low plasma glucose level is required, typically defined as $[\\text{glucose}]  55\\,\\text{mg/dL}$.\n    -   The patient's measured glucose is $[\\text{glucose}] = 45\\,\\text{mg/dL}$.\n    -   Since $45  55$, this criterion is met.\n\n2.  **Plasma Insulin:** In a healthy individual, hypoglycemia strongly suppresses insulin secretion. An inappropriately elevated insulin level is a key diagnostic feature. The threshold is typically $[\\text{insulin}] \\ge 3\\,\\mu\\text{U/mL}$.\n    -   The patient's measured insulin is $[\\text{insulin}] = 6\\,\\mu\\text{U/mL}$.\n    -   Since $6 \\ge 3$, this criterion is met. The insulin level is inappropriately high for the degree of hypoglycemia.\n\n3.  **Plasma C-peptide:** C-peptide is co-secreted with endogenous insulin in equimolar amounts. A normal or elevated C-peptide level in the setting of hyperinsulinemic hypoglycemia confirms an endogenous source of insulin (i.e., from the patient's own pancreas) and rules out the surreptitious administration of exogenous insulin. The threshold is typically $[\\text{C-peptide}] \\ge 0.2\\,\\text{nmol/L}$ (equivalent to $0.6\\,\\text{ng/mL}$).\n    -   The patient's measured C-peptide is $[\\text{C-peptide}] = 0.3\\,\\text{nmol/L}$.\n    -   Since $0.3 \\ge 0.2$, this criterion is met.\n\n4.  **Plasma Proinsulin:** Insulinomas are often inefficient at processing proinsulin to mature insulin, leading to a disproportionate secretion of proinsulin. An elevated proinsulin level is highly suggestive of an insulinoma. A common diagnostic threshold is $[\\text{proinsulin}] \\ge 5\\,\\text{pmol/L}$.\n    -   The patient's measured proinsulin is $[\\text{proinsulin}] = 15\\,\\text{pmol/L}$.\n    -   Since $15 \\ge 5$, this criterion is met.\n\n5.  **Screen for Hypoglycemic Agents:** It is crucial to exclude factitious hypoglycemia caused by insulin secretagogues like sulfonylureas or meglitinides. These drugs stimulate endogenous insulin and C-peptide secretion, mimicking the biochemical profile of an insulinoma.\n    -   The problem states that the \"comprehensive sulfonylurea and meglitinide screen is negative.\"\n    -   This criterion is met, ruling out these specific exogenous causes.\n\nAll five biochemical criteria for establishing a diagnosis of endogenous hyperinsulinemic hypoglycemia, consistent with an insulinoma, are satisfied by the patient's data. Therefore, according to the problem's definition, the diagnostic indicator $D$ must be assigned the value $1$.\n\nThe final computation is:\n-   Hypoglycemia confirmed: $45  55$.\n-   Inappropriate hyperinsulinemia confirmed: $6 \\ge 3$.\n-   Endogenous source confirmed by C-peptide: $0.3 \\ge 0.2$.\n-   Inefficient processing confirmed by proinsulin: $15 \\ge 5$.\n-   Exogenous drug stimulation excluded: Negative screen.\n\nSince all conditions are met, $D=1$.", "answer": "$$\\boxed{1}$$", "id": "4652669"}, {"introduction": "Accurate staging is the cornerstone of oncologic management, providing a universal language to define prognosis and guide therapeutic strategy. For pancreatic neuroendocrine tumors, the American Joint Committee on Cancer (AJCC) TNM system quantifies the anatomical extent of disease by evaluating the primary tumor ($T$), regional lymph node involvement ($N$), and distant metastasis ($M$). This practice problem requires you to synthesize clinical and pathological findings to assign the correct TNM classification and overall stage, a fundamental skill for any surgeon managing these complex neoplasms. [@problem_id:4422979]", "problem": "A patient with clinically suspected Zollinger–Ellison syndrome has a biopsy-proven pancreatic neuroendocrine tumor consistent with gastrinoma. Cross-sectional imaging shows a solitary, well-circumscribed lesion measuring $2.8\\ \\mathrm{cm}$ confined to the pancreas without radiographic evidence of invasion into adjacent organs or major vessels. Surgical pathology identifies $3$ positive peripancreatic regional lymph nodes. Intraoperative ultrasound and subsequent magnetic resonance imaging confirm a single hepatic lesion measuring $1.5\\ \\mathrm{cm}$ that is histologically compatible with metastatic neuroendocrine tumor. Using the American Joint Committee on Cancer (AJCC) Tumor–Node–Metastasis (TNM) system for pancreatic neuroendocrine tumors, which composite category and stage group best classify this tumor?\n\nChoose the single best option:\n\nA. $T1\\ N1\\ M1\\mathrm{a}$; Stage $\\mathrm{III A}$\n\nB. $T2\\ N1\\ M1\\mathrm{a}$; Stage $\\mathrm{IV}$\n\nC. $T2\\ N0\\ M1\\mathrm{b}$; Stage $\\mathrm{IV}$\n\nD. $T3\\ N1\\ M0$; Stage $\\mathrm{III B}$\n\nE. $T2\\ N1\\ M0$; Stage $\\mathrm{III}$", "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n- **Diagnosis:** Biopsy-proven pancreatic neuroendocrine tumor (pNET), specifically a gastrinoma, associated with clinically suspected Zollinger–Ellison syndrome.\n- **Primary Tumor (T):** A solitary, well-circumscribed lesion measuring $2.8\\ \\mathrm{cm}$ confined to the pancreas. There is no radiographic evidence of invasion into adjacent organs or major vessels.\n- **Regional Lymph Nodes (N):** Surgical pathology identifies $3$ positive peripancreatic regional lymph nodes.\n- **Distant Metastasis (M):** Intraoperative ultrasound and subsequent magnetic resonance imaging confirm a single hepatic lesion measuring $1.5\\ \\mathrm{cm}$, which is histologically compatible with metastatic neuroendocrine tumor.\n- **Question:** Determine the composite American Joint Committee on Cancer (AJCC) Tumor–Node–Metastasis (TNM) category and stage group for this tumor.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective. It provides a standard clinical scenario and asks for the application of a well-defined, internationally recognized classification system, the AJCC TNM staging for pancreatic neuroendocrine tumors. The data provided (tumor size, lymph node status, and metastasis status) are necessary and sufficient for this classification. The language is precise and clinical. The problem does not violate any principles of scientific validity, logic, or objectivity.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be derived by applying the AJCC Cancer Staging Manual, 8th Edition, criteria for Neuroendocrine Tumors of the Pancreas.\n\n### Derivation of Solution\nThe TNM staging is determined by assessing the primary tumor (T), regional lymph nodes (N), and distant metastasis (M) components individually.\n\n**T (Primary Tumor) Classification:**\nThe AJCC criteria for the T category of pancreatic neuroendocrine tumors are based on tumor size and local invasion.\n- $T1$: Tumor limited to the pancreas, $\\le 2\\ \\mathrm{cm}$ in greatest dimension.\n- $T2$: Tumor limited to the pancreas, $ 2\\ \\mathrm{cm}$ but $\\le 4\\ \\mathrm{cm}$ in greatest dimension.\n- $T3$: Tumor limited to the pancreas and $ 4\\ \\mathrm{cm}$ in greatest dimension; OR tumor invades duodenum or common bile duct.\n- $T4$: Tumor invades adjacent organs or the wall of large vessels.\n\nThe patient's tumor measures $2.8\\ \\mathrm{cm}$ and is confined to the pancreas. Since $2\\ \\mathrm{cm}  2.8\\ \\mathrm{cm} \\le 4\\ \\mathrm{cm}$, the primary tumor is classified as **T2**.\n\n**N (Regional Lymph Nodes) Classification:**\nThe N category is based on the presence or absence of regional lymph node metastasis.\n- $N0$: No regional lymph node metastasis.\n- $N1$: Regional lymph node metastasis.\n\nThe patient has $3$ positive peripancreatic regional lymph nodes. The presence of any regional lymph node metastasis, regardless of the number of nodes, defines this category. Therefore, the lymph node status is classified as **N1**.\n\n**M (Distant Metastasis) Classification:**\nThe M category is based on the presence and location of distant metastases.\n- $M0$: No distant metastasis.\n- $M1$: Distant metastasis.\n    - $M1\\mathrm{a}$: Metastasis confined to the liver.\n    - $M1\\mathrm{b}$: Metastasis in at least one extrahepatic site.\n    - $M1\\mathrm{c}$: Both hepatic and extrahepatic metastases.\n\nThe patient has a single, confirmed metastatic lesion in the liver and no evidence of extrahepatic spread. This is classified as **M1a**.\n\n**Composite TNM Category and Stage Group:**\nCombining the individual components gives the full TNM classification: **$T2\\ N1\\ M1\\mathrm{a}$**.\n\nNext, we use the TNM classification to determine the prognostic stage group.\n- Stage I: $T1, N0, M0$\n- Stage IIA: $T2, N0, M0$\n- Stage IIB: $T3, N0, M0$\n- Stage III: Any $T, N1, M0$  or $T4, N0, M0$\n- Stage IV: Any $T$, Any $N$, $M1$\n\nThe patient's classification includes $M1$, indicating distant metastasis. According to the AJCC 8th Edition, any tumor with distant metastasis (any $T$, any $N$, $M1$) is classified as **Stage IV**.\n\nTherefore, the correct classification for this patient is $T2\\ N1\\ M1\\mathrm{a}$, Stage $\\mathrm{IV}$.\n\n### Evaluation of Options\n\n**A. $T1\\ N1\\ M1\\mathrm{a}$; Stage $\\mathrm{III A}$**\n- The $T$ category is incorrect. The tumor size of $2.8\\ \\mathrm{cm}$ corresponds to $T2$, not $T1$.\n- The Stage Group is incorrect. $M1$ disease is defined as Stage $\\mathrm{IV}$, not Stage $\\mathrm{III A}$.\n- **Verdict: Incorrect.**\n\n**B. $T2\\ N1\\ M1\\mathrm{a}$; Stage $\\mathrm{IV}$**\n- The $T$ category is correct ($T2$ for a $2.8\\ \\mathrm{cm}$ tumor).\n- The $N$ category is correct ($N1$ for positive regional nodes).\n- The $M$ category is correct ($M1\\mathrm{a}$ for liver-only metastasis).\n- The Stage Group is correct (Stage $\\mathrm{IV}$ for any $M1$ disease).\n- **Verdict: Correct.**\n\n**C. $T2\\ N0\\ M1\\mathrm{b}$; Stage $\\mathrm{IV}$**\n- The $N$ category is incorrect. The presence of $3$ positive nodes makes it $N1$, not $N0$.\n- The $M$ subcategory is incorrect. Liver-only metastasis is $M1\\mathrm{a}$, not $M1\\mathrm{b}$ (extrahepatic metastasis).\n- **Verdict: Incorrect.**\n\n**D. $T3\\ N1\\ M0$; Stage $\\mathrm{III B}$**\n- The $T$ category is incorrect. A $2.8\\ \\mathrm{cm}$ tumor without duodenal/bile duct invasion is $T2$, not $T3$.\n- The $M$ category is incorrect. The patient has a liver metastasis, so the status is $M1$, not $M0$.\n- The Stage Group is incorrect. $M1$ disease is Stage $\\mathrm{IV}$. Also, Stage $\\mathrm{III B}$ is not a valid stage group for pancreatic neuroendocrine tumors in the AJCC 8th edition.\n- **Verdict: Incorrect.**\n\n**E. $T2\\ N1\\ M0$; Stage $\\mathrm{III}$**\n- The $M$ category is incorrect. The patient has a confirmed liver metastasis, making the status $M1$, not $M0$.\n- The Stage Group is incorrect. Because the patient is $M1$, the stage is $\\mathrm{IV}$, not $\\mathrm{III}$.\n- **Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "4422979"}, {"introduction": "One of the most common and debated scenarios in pancreatic surgery is the management of a small, incidentally discovered, nonfunctional pancreatic neuroendocrine tumor (NF-pNET). The decision between active surveillance and surgical resection requires a sophisticated balance of oncologic risk against the significant morbidity of pancreatectomy. This problem simulates this complex decision-making process, tasking you with integrating tumor size, grade, and imaging features to formulate a sound, evidence-based management plan that includes specific criteria for observation and intervention. [@problem_id:4652602]", "problem": "A $58$-year-old individual undergoes abdominal imaging for nephrolithiasis and is incidentally found to have a well-circumscribed pancreatic tail lesion measuring $1.5\\,\\text{cm}$ on a pancreas-protocol multiphasic Computed Tomography (CT) scan. Magnetic Resonance Imaging (MRI) confirms a hyperenhancing $1.5\\,\\text{cm}$ lesion without main pancreatic duct dilation (main duct caliber $\\leq 3\\,\\text{mm}$), without abutment of the splenic artery or vein, and without suspicious peripancreatic lymph nodes. Endoscopic Ultrasound (EUS) with Fine-Needle Aspiration (FNA) shows a well-differentiated pancreatic neuroendocrine tumor (pNET) with a Ki-$67$ index of $2\\%$ and low mitotic activity, consistent with World Health Organization (WHO) grade $1$. Fasting serum hormone panel (insulin, glucagon, gastrin, vasoactive intestinal peptide, somatostatin) is normal, and the patient endorses no symptoms of hormone excess. There is no evidence of metastatic disease on cross-sectional imaging. The patient has well-controlled hypertension, no history of pancreatitis, and expresses willingness for close follow-up if clinically justified.\n\nUsing fundamental oncologic and surgical principles that relate tumor size, differentiation, and proliferative index to metastatic potential and growth kinetics, and balancing these against operative risks of distal pancreatectomy (including pancreatic fistula, endocrine and exocrine insufficiency, and splenic sequelae), which of the following option best specifies appropriate criteria for initial observation versus resection and delineates a scientifically sound surveillance and intervention plan for this patient?\n\nA. Offer active surveillance because the tumor is nonfunctional, $\\lt 2\\,\\text{cm}$, and WHO grade $1$, with no ductal dilation, vascular involvement, or nodal disease; institute MRI or pancreas-protocol CT every $6$ months for $2$ years then annually, with EUS if interval growth is suspected; proceed to resection if any of the following occur: growth $\\gt 0.5\\,\\text{cm}$ per year or $\\geq 20\\%$ diameter increase, size reaches $\\geq 2\\,\\text{cm}$, development of symptoms, new lymphadenopathy or duct dilation, or repeat sampling shows Ki-$67 \\geq 3\\%$.\n\nB. Proceed with immediate distal pancreatectomy with splenectomy because all nonfunctional pNETs in the tail that are $\\geq 1\\,\\text{cm}$ have an unacceptably high nodal metastasis rate; observation is not appropriate regardless of grade or imaging features.\n\nC. Perform enucleation without lymph node assessment because the lesion is $\\lt 2\\,\\text{cm}$ and low grade; no structured surveillance is necessary beyond a single postoperative CT at $12$ months given the low malignant potential.\n\nD. Observation is appropriate only in patients with prohibitive operative risk or age $\\geq 75$ years; otherwise, resect all nonfunctional pNETs $\\gt 1\\,\\text{cm}$; if observing, trigger surgery only if growth exceeds $1\\,\\text{mm}$ per year, as smaller changes fall within measurement error.", "solution": "The decision between observation and resection for small, incidentally identified, nonfunctional pancreatic neuroendocrine tumors (pNETs) should be derived from core oncologic principles and well-established clinical observations:\n\n1. Tumor biology and risk stratification: For well-differentiated pNETs, the risk of nodal and distant metastasis correlates with size and proliferative index. Nonfunctional pNETs that are $\\lt 2\\,\\text{cm}$ and WHO grade $1$ (Ki-$67 \\lt 3\\%$) have relatively indolent behavior and lower metastatic potential compared with larger or higher-grade tumors.\n\n2. Growth kinetics: Small, low-grade pNETs often exhibit slow growth. Surveillance frameworks rely on detecting clinically meaningful growth, commonly framed as an absolute increase (for example, $\\gt 0.5\\,\\text{cm}$ per year) or a relative increase (for example, $\\geq 20\\%$ in diameter), which exceeds typical inter-study measurement variability and correlates with biological progression.\n\n3. Anatomic and imaging features: Absence of main pancreatic duct dilation, vascular abutment or invasion, and lymphadenopathy on high-quality imaging reduces the likelihood of occult aggressive behavior and the need for immediate intervention.\n\n4. Surgical risk-benefit calculus: Distal pancreatectomy, even when spleen-preserving, carries nontrivial morbidity, including clinically relevant postoperative pancreatic fistula (on the order of approximately $10$–$20\\%$), and potential long-term endocrine (diabetes mellitus) and exocrine insufficiency. Splenectomy adds risks related to overwhelming post-splenectomy infection and requires vaccination. Avoiding surgery is reasonable if oncologic risk is low and the patient is reliable for surveillance.\n\n5. Patient factors: Absence of hormone excess symptoms (nonfunctional tumor), patient willingness and ability to adhere to surveillance, and lack of prohibitive comorbidity inform shared decision-making.\n\nApplying these principles to the presented patient with a $1.5\\,\\text{cm}$, nonfunctional, well-differentiated, WHO grade $1$ pNET without ductal dilation, vascular involvement, nodes, or metastasis, observation can be appropriate if a rigorous surveillance plan and clear intervention triggers are defined.\n\nOption-by-option analysis:\n\nA. This option articulates selection criteria for observation that align with the risk profile: nonfunctional status, size $\\lt 2\\,\\text{cm}$, WHO grade $1$ (Ki-$67 \\lt 3\\%$), and reassuring imaging (no ductal dilation, vascular involvement, or nodes). It also specifies a surveillance cadence (MRI or pancreas-protocol CT every $6$ months for $2$ years, then annually) that corresponds to capturing early growth while limiting radiation exposure; EUS can resolve uncertainties about growth or morphology. The intervention triggers (growth $\\gt 0.5\\,\\text{cm}$ per year or $\\geq 20\\%$ increase, size $\\geq 2\\,\\text{cm}$, new symptoms, new lymphadenopathy or duct dilation, or Ki-$67$ progression to $\\geq 3\\%$ on repeat sampling) are grounded in the distinction between indolent and more aggressive behavior and exceed known measurement error. This reflects a sound, evidence-aligned, risk-adaptive approach that balances oncologic safety with surgical morbidity. Verdict — Correct.\n\nB. This option mandates immediate resection and splenectomy for all tail pNETs $\\geq 1\\,\\text{cm}$ regardless of grade, functionality, or imaging. While the risk of nodal metastasis is not zero for small pNETs, high-quality data and consensus guidelines support consideration of active surveillance for selected nonfunctional, $\\lt 2\\,\\text{cm}$, well-differentiated tumors with reassuring imaging due to their relatively favorable biology and the morbidity of distal pancreatectomy. A blanket rule at the $1\\,\\text{cm}$ threshold disregards tumor grade and other risk-modifying features and overestimates the net benefit of surgery in many patients. Verdict — Incorrect.\n\nC. This option proposes enucleation without lymph node assessment and minimal follow-up. Although enucleation can be considered for small lesions that are exophytic and sufficiently distant from the main pancreatic duct, omission of lymph node assessment in nonfunctional pNETs risks under-staging because nodal metastasis can occur even in small tumors. Furthermore, advocating no structured surveillance after a single $12$-month scan neglects the potential for late growth or recurrence. This plan underestimates the need for appropriate staging and longitudinal evaluation. Verdict — Incorrect.\n\nD. This option restricts observation only to very elderly or prohibitive-risk patients and suggests a resection threshold of $\\gt 1\\,\\text{cm}$. It also proposes a growth trigger of $1\\,\\text{mm}$ per year, which is within the range of inter-study measurement variability for small pancreatic lesions and thus not a reliable biologic signal. Both the selection criteria and the trigger thresholds are miscalibrated relative to the biology of well-differentiated pNETs and the accuracy limits of imaging. Verdict — Incorrect.", "answer": "$$\\boxed{A}$$", "id": "4652602"}]}